“Important safety information on the use of IRINOTECAN MEDAC (irinotecan hydrochloride): Drug toxicity in patients with reduced activity of UGT1A1

14.12.2021 1819 views

«Важлива інформація щодо безпеки застосування ІРИНОТЕКАН МЕДАК (іринотекану гідрохлорид): Лікарська токсичність у пацієнтів зі зниженою активністю UGT1A1PDF · 2.1 МБ

Завантажити

“Important safety information on the use of IRINOTECAN MEDAC (irinotecan hydrochloride): Drug toxicity in patients with reduced activity of UGT1A1

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

“Important safety information on the use of IRINOTECAN MEDAC (irinotecan hydrochloride): Drug toxicity in patients with reduced activity of UGT1A1

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration